Skip to main content

Table 4 Comparison of prospective FEV1 decline, exacerbation rate and respiratory symptoms between those in the discordant group (Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN) with CT findings of emphysema or functional small airways disease, and those without

From: Heterogeneous burden of lung disease in smokers with borderline airflow obstruction

  Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN (discordant group, n = 161)
With fSAD or emphysema (44%) Without fSAD or emphysema (56%) *Adjusted p-value Unadjusted p-value
Annual change in FEV1 (ml/year) −65.6 ± 113.0 −59.8 ± 130.6 0.26 0.79
Exacerbation (#/year) 0.13 ± 0.42 0.06 ± 0.24 0.90 0.25
COPD Assessment Test (CAT) 11.43 ± 7.44 9.88 ± 7.25 0.55 0.22
Chronic bronchitis (%) 14.3 ± 35.3 18.3 ± 38.9 0.58 0.52
FEF25–75% % predicted 60.0 ± 11.6 62.2 ± 10.7 0.87 0.24
  1. *Multivariate model adjusting for age, gender, race, pack year, and current smoking status